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Summary
Background: Myc is a well-known proto-oncogene, but
its functions in normal tissue remain enigmatic. In adult
epidermis, Myc stimulates exit from the stem cell com-
partment, decreasing cell adhesion and, by an unknown
mechanism, triggering proliferation of transit-amplifying
cells.
Results: We describe a novel direct target gene of Myc,
Misu, that is expressed at low levels in normal epidermis
but is upregulated on Myc activation. Misu encodes
a previously uncharacterized RNA methyltransferase
with high sequence homology to NSun2 and defines
a new family of mammalian SUN-domain-containing
proteins. The nucleolar localization of Misu is dependent
on RNA polymerase III transcripts, and knockdown of
Misu decreases nucleolar size. In G2 phase of the cell
cycle, Misu is found in cytoplasmic vesicles, and it dec-
orates the spindle in mitosis. Misu expression is highest
in S phase, and RNAi constructs block Myc-induced
keratinocyte proliferation and cell-cycle progression.
Misu is expressed at low levels in normal tissues, but
is highly induced in a range of tumors. Growth of human
squamous-cell-carcinoma xenografts is decreased by
Misu RNAi.
Conclusions: Misu is a novel downstream Myc target
that methylates RNA polymerase III transcripts. Misu
mediates Myc-induced cell proliferation and growth
and is a potential target for cancer therapies.
Introduction
Myc is a nuclear protein that heterodimerizes with the
ubiquitously expressed protein Max to function as a
sequence-specific transcription factor, binding to E box
elements [1, 2]. Myc/Max heterodimers activate gene
transcription by recruiting a protein complex containing
histone-acetyltransferase activity [3]. Myc and Max re-
press transcription by interfering with the transcriptional
activator Miz-1 or recruiting a corepressor containing
the histone deacetylase complex [4, 5].
Overexpression of Myc promotes tumorigenesis, but
its functions in normal cells are still enigmatic. Recent
studies have revealed a role in regulating adult stem
cell homeostasis in the epidermis [6–8], intestinal epi-
thelium, and blood [9]. In the epidermis and hemopoietic
*Correspondence: michaela.frye@cancer.org.uk (M.F.); fiona.watt@
cancer.org.uk (F.M.W.)tissue, Myc induces exit from the stem cell niche by
downregulating genes encoding proteins involved in
cell adhesion [6, 8–11]. In addition, Myc impairs epider-
mal cell migration, which may explain why sebocyte
differentiation is promoted at the expense of the hair
lineages [8, 10, 11].
Myc plays a direct role in controlling cell division and
growth. Many Myc target genes encode components of
the protein-synthesis machinery [10]. In addition, Myc
directly activates RNA polymerase (pol) III transcription
and enhances expression of transfer RNAs (tRNA), 5S
rRNA, and a subset of other small RNAs [12]. Myc also
activates RNA pol I and thereby induces ribosomal
RNA synthesis [13, 14]. As a result, Myc overexpression
leads to an increase in nuclear, nucleolar, and cell size
[15]. Nucleolar activity plays an important role in cell-cy-
cle control [16].
In this report, we describe a novel gene that is acti-
vated by Myc and encodes a previously uncharacterized
RNA methyltransferase named Misu. We show that Misu
regulates nucleolar size, is a component of the mitotic
spindle, and mediates the effects of Myc on epidermal
cell growth and proliferation. Misu is expressed at low
levels in most normal tissues and is overexpressed in
different types of tumor. Because inhibition of Misu re-
duces tumor formation in vivo, it may be a good target
for anticancer drugs.
Results
Misu Expression Correlates with Activation of Myc
In Vitro and In Vivo
In order to analyze how Myc exerts its effect in the epi-
dermis, we performed microarray analysis with RNA ex-
tracted from whole skin of K14MycER transgenic mice
and wild-type littermates [10]. In K14MycER mice, Myc
is activated by topical application of 4-hydroxy-tamoxi-
fen (4OHT).
When Myc was activated for 1 or 4 days in K14MycER
epidermis, there was strong upregulation of a mRNA
with accession number BC013625 (Figure 1A). In wild-
type animals, expression of BC013625 mRNA was low,
whether or not the skin was treated with 4OHT (Fig-
ure 1A). The microarray results were validated by north-
ern blotting total RNA from wild-type and transgenic
back skin (Figure 1B).
BLAST searches revealed BC013625 to encode
a novel protein with a conserved SUN domain. SUN,
also known as Fmu, was first described in E. coli and
catalyzes the formation of 5-methylcytidine (m5C) in
16S rRNA [17, 18]. We named the new protein Misu, for
Myc-induced SUN-domain-containing protein. The pro-
tein with the highest overall homology to Misu (36%) is
yeast NCL1 (or Trm4) [19], which is a tRNA m5C methyl-
transferase (MTase) [20]. Misu showed weak similarity
(23%) to a human protein called p120 or nucleolar-asso-
ciated antigen. p120 is expressed in rapidly dividing
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972Figure 1. Expression of Misu RNA Correlates with Myc Activation
(A) RNA expression profile of Misu in skin of K14MycER-transgenic and wild-type mice that were untreated (0 days) or treated with 4OHT (1 day
and 4 days). Error bars represent standard deviations.
(B) Northern blot of total RNA from skin of wild-type (wt) and transgenic (tg) mice, treated for 4 days or 9 days with 4OHT, probed for Misu (arrow)
or, as a loading control, 18S RNA.
(C) Sequence surrounding the first conserved cysteine within the SUN domain of Misu, DNA MTases (HhaI, EcoRI, mDnmt1), and RNA MTases
(NCL1, p120, Nop2).
(D) Tissue northern blot probed for Misu (arrow).
(E–L) In situ hybridization of Misu in back skin of wild-type mouse treated with 4OHT for 4 days (E and F) or K14MycER transgenic untreated (G
and H) or treated with 4OHT for 1 day (I and J) or 4 days (K and L). Bright- and dark-field views of the same sections are shown. Scale bar rep-
resents 100 mm.
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Myc, with RNA Methyl Transferase Activity
and Conserved Genomic Organization
(A) Mouse and (B) human Misu genes consist
of 19 exons.
(C and D) Western blots showing upregu-
lation of Misu by activation of MycER in hu-
man keratinocytes (k) compared to controls
(k-pBabe; k-106ER). Actin and tubulin served
as loading controls.
(E) Three putative Myc binding sites in the
Misu promoter.
(F) RT-PCR showing amplification of Misu in
keratinocytes infected with MycER but not
106ER after 30 min pretreatment with cyclo-
heximide. RNA was isolated 0.5, 1, and 4 hr
after treatment with 4OHT.
(G) ChIP of Misu promoter with antibody to
Myc. PCR of input control amplifies Misu pro-
moter in keratinocytes infected with empty
vector (k-pBabe), a dominant-negative mu-
tant of Myc (k-MycDER), and MycER
(k-MycER). One control was isotype-matched
antibody (upper panel). Without 4OHT, the
Misu promoter is detected equally in all sam-
ples except the control (middle panel). After 2
days of 4OHT treatment, Misu can be de-
tected in k-MycER, to a lower extent in
k-pBabe, but not in k-MycDER (lower panel).
M denotes molecular weight markers.
(H) Incorporation of radioactive (14C)-labeled
SAM into tRNA (left-hand panel) or hemime-
thylated DNA (right-hand panel). As negative
controls, Misu and Dnmt1 were transcribed
in the anti-sense direction (control). DMisu
is the S3 splice variant. Error bars represent
standard deviations.cells [21] and shows substantial homology (67%) to the
yeast rRNA m5C MTase Nop2 [22].
Within the SUN domain, a pair of conserved cysteines,
approximately 50 amino acids apart, represent the po-
tential active site [22]. Figure 1C shows the highly con-
served core sequence surrounding the first cysteine
that is found in Misu, NCL1, p120, and Nop2 (Figure 1C)
[19, 20]. This part of the SUN domain has sequence and
structural similarities with motif IV of DNA:m5C MTases
such as bacterial HhaI and EcorII and mammalian
Dnmt1 (Figure 1C) [20, 23]. The conserved sequence
motifs and structural homologies among S-adenosyl-
L-methionine-dependent DNA and RNA MTases
strongly suggest an evolutionary relationship [23, 24].
Misu mRNA was present in all tissues analyzed (Fig-
ure 1D). In wild-type mouse skin treated for 4 days with
4OHT (Figures 1E and 1F) or in untreated K14MycER
skin (Figures 1G and 1H), Misu expression was very
weak. Following 4OHT treatment of transgenic skin (Fig-
ures 1I–1L), Misu expression was strongly upregulated in
all cells that express the K14 promoter: the basal layer of
interfollicular epidermis, the periphery of the sebaceous
glands, and along the hair-follicle outer-root sheath [10].Misu Defines a New Family of Mammalian
SUN-Domain-Containing Genes and Is
Alternatively Spliced
BLAST searches revealed five previously uncharacter-
ized mouse SUN-domain-containing proteins, in addi-
tion to Misu and p120 (Figure S1A in the Supplemental
Data available online). One, NSun2 (accession number
NM_145354), has regions of sequence identity with
Misu, but the predicted protein is smaller (691 versus
757 amino acids; Figure S1A). However, GenBank entry
NP_060225 for human NSun2 corresponds to the pre-
dicted full-length sequence of human Misu. Misu local-
ized to chromosome 13B3 in mouse (Figure 2A) and
5p15 in human (Figure 2B).
Human and mouse Misu are each encoded by 19
exons (Figures 2A and 2B). We obtained evidence for
the existence and expression of three splice variants
(Figures S1 and S2), two of which lack an intact SUN do-
main and can therefore function as dominant-negative
inhibitors of Misu (Figure 2H, DMisu).
To analyze whether Myc activation increased Misu
protein expression, we performed western blotting of
4OHT-treated cultured human keratinocytes that had
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MycER) (Figures 2C and 2D). As controls, keratinocytes
expressing the empty retroviral vector (k-pBabe) or
a mutant form of MycER with a deletion within the trans-
activation domain (k-106ER) were also examined (Fig-
ures 2C and 2D). Misu protein expression was increased
in k-MycER within 12 hr of 4OHT treatment, but not in
control cells (Figure 2D).
There are three putative binding sites for Myc up-
stream from the predicted start methionine of human
Misu (Figure 2E). To analyze whether Misu RNA synthe-
sis was independent of de novo protein synthesis, we
performed RT-PCR on MycER expressing keratinocytes
that had been treated with cycloheximide for 30 min
prior to addition of 4OHT (Figure 2F). Misu expression
was detected in keratinocytes transduced with MycER,
but not in control cells transduced with Myc106ER
(Figure 2F).
We also performed chromatin immunoprecipitation
(ChIP) analysis in primary human keratinocytes (Fig-
ure 2G). The Misu promoter was amplified by PCR in
all samples prior to immunoprecipitation with an anti-
body to Myc (Input, Figure 2G, upper panel). As controls
we used an isotype-matched antibody (control) or ly-
sates from cells transduced with a Myc mutant
(MycDER) that is unable to bind to E boxes (MycDER,
Figure 2G) [25]. Without 4OHT treatment, the intensity
of the PCR fragment was comparable in all samples, in-
dicating that the promoter was precipitated by endoge-
nous Myc (Figure 2G, middle panel). On treatment with
4OHT, the interaction of Myc with the Misu promoter
was increased in k-MycER, but not in k-pBabe, and
was blocked in k-MycDER (Figure 2G, lower panel).
We concluded that Misu is a direct downstream target
of Myc.
Misu Methylates RNA
To determine whether Misu had methyltransferase ac-
tivity, we performed methylation assays, measuring
the incorporation of 14C-labeled S-adenosyl-L-methio-
nine (SAM) into RNA (Figure 2H). Given that yeast
RNA:m5C MTases can methylate a wide range of RNAs
in vitro [26], and Misu showed the highest homology to
NCL1, a tRNA methyltransferase, we used tRNA as a rep-
resentative RNA target substrate. Full-length Misu cDNA
was in vitro translated and incubated with tRNA (Fig-
ure 2H, left panel). As a negative control we used Misu
cDNA transcribed in the antisense direction (Figure 2H,
left panel, control).
We detected a 2.5-fold increase in 14C incorporation
into tRNA in the presence of Misu compared to controls
(Figure 2H, left panel). Misu also catalyzed 14C incorpo-
ration into rRNA (Figure S3E). DNase treatment did not
abolish the methylation activity of Misu toward RNA
(data not shown). There was no significant 14C-SAM in-
corporation into tRNA in the presence of the 60 kDa
Misu splice variant (DMisu, corresponding to the S3
splice variant initiated in exon 7; Figure S2B) or SssI,
a DNA MTase isolated from Spiroplasma sp. (Figure 2H).
In contrast, incorporation of 14C-SAM into hemimethy-
lated DNA was stimulated by SssI and the DNA MTase
Dnmt1 (Figure 2H, right panel). In vitro, Misu and
Dnmt1 showed comparable methylation activities to-
ward their target substrates (Figure 2H).Subcellular Distribution of Misu Changes during
the Cell Cycle
Misu methytransferase activity in vivo will depend on its
nuclear location. rRNA:m5C MTases are found in the nu-
cleoli [27]. tRNA MTases are found both in the nucleoli
and close to the nuclear envelope, where the splicing
and processing of tRNA takes place [28, 29]. In keratino-
cytes and SZ95 sebocytes, the level of Misu varied
throughout the cell cycle, with lowest expression in early
G1 (Figures 3A–3C). In G1, Misu was predominantly
found in the nucleoli, where it colocalized with nucleolin
(arrows, Figures 3D–3F). In S phase cells, the number
and size of nucleoli increase, and nucleolin is found in
both nucleoli and nucleoplasm (Figure 3D, asterisks). S
phase cells had the highest levels of Misu, which was
distributed more uniformly throughout the nucleus (as-
terisks, Figures 3E and 3F) than in G1. We confirmed
that Misu was upregulated during S phase by western
blotting SZ95 cells that had been treated for 4 hr with tri-
chostatin A (TSA) or Actinomycin D (ActD) to trigger ac-
cumulation of S phase cells (Figures 3M and 3N). Misu
was also upregulated in FACS-sorted populations of S
phase SZ95 cells that had not been treated with drugs
(Figure 3O).
In a small percentage of cells in G2, Misu was de-
tected in cytoplasmic vesicles that did not correspond
with mitochondria [30] (arrows, Figures 3G–3I). In M
phase, Misu was found along the spindle and colocal-
ized with g-tubulin at centrioles (Figures 3J–3L). This
distribution has never been described for RNA MTases,
but it has been reported for ATRX [31]. ARTX is a centro-
meric heterochromatin binding protein, involved in
methylating repetitive DNA sequences, that is required
for meiotic spindle organization.
Endogenous Nucleolar Localization of Misu
Is Dependent on RNA Species Transcribed
by RNA Pol III
In order to examine whether the localization of Misu was
dependent on the presence of nucleolar-RNA species,
we treated cells with RNaseA prior to immunostaining
(Figures 4A–4H). RNaseA treatment abolished the local-
ization of Misu in nucleoli (Figure 4B), but not in centri-
oles and cytoplasmic vesicles (Figure 4C, arrow and
data not shown). Like Misu, the localization of nucleolin
was sensitive to RNaseA but not to DNase treatment
(Figures 4D–4H).
After treatment with 0.05 mg/ml, Actinomycin D, which
selectively inhibits RNA pol I, Misu localized to the peri-
nucleolar compartment, a region highly enriched in RNA
pol III transcripts (Figure 4J, arrow) [32]. Ten micrograms
per milliliter a-amanitin, which selectively inhibits RNA
pol II, had no effect on the localization of Misu (Figure 4K,
arrow). In contrast, 100 mg/ml a-amanitin inhibits RNA
pol II and III and depleted Misu from the nucleoli
(Figure 4L, arrow). We conclude that the nucleolar local-
ization of Misu depended on the presence of RNA pol III
transcripts.
Misu Is Required for Myc-Induced Proliferation
To examine whether Misu was required for Myc-induced
proliferation, we generated three different Misu RNAi
constructs (RNAi1,3,4). RNAi1 and 3 inhibited Misu
expression by a maximum of 50%, whereas RNAi4
Misu, a Myc-Regulated RNA Methyltransferase
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and Regulation during the Cell Cycle
(A–L) Immunofluorescence staining for Misu
(green) and nucleolin (red in [A]–[F]) and g-tu-
bulin (gTub, red in [J]–[L]) or mitochondrial
dye (Mito, red in [G]–[I]) with DAPI (blue)
counterstain. (A–C) Arrows show colocaliza-
tion of Misu with nucleolin at nucleoli. (D–F)
Cells in G1 (arrow) and S phase (asterisks)
are shown. (G–I) Cytoplasmic Misu does not
colocalize with mitochondria (arrow). (J–L)
Colocalization of Misu with g-tubulin at spin-
dle poles.
(M) Cells arrested in S phase or G2/M phase
of the cell cycle after treatment with trichos-
tatin A (TSA) or Actinomycin D (ActD). Error
bars represent standard deviations.
(N) Western blot of Misu before (0 hr) and after
treatment with TSA and ActD for 4 hr.
(O) Western blot of Misu in FACS-sorted
G1-phase and S phase SZ95 cells.decreased Misu expression by up to 90% (Figure 4M,
upper panel). These results were confirmed by Misu im-
munofluorescence staining of keratinocytes (Figures
4N–4Q) and SZ95 cells (Figures S4A–S4H).
MycER activation in SZ95 cells or keratinocytes re-
sulted in an increase in nucleolar size, accompanied
by increased deposition of Misu, nucleolin, and Ki67
(Figures 4R–4T; data not shown). Introduction of Misu
RNAi into MycER-expressing cells significantly reduced
nucleolar size, to a level comparable to control cells (Fig-
ures 4R–4U).
When primary human keratinocytes were transduced
with a Misu RNAi4 retroviral vector, proliferation was
markedly decreased compared to empty-vector-in-
fected controls or keratinocytes infected with RNAi1 or
3 (Figures 5A and 5B). Proliferation of human keratino-
cytes was not affected by a scrambled RNAi sequence
(Figures S4I and S4J).
Misu RNAi4 abolished the MycER-activation-induced
increase in growth rate of keratinocytes (Figures 5B and
5C) and prevented Myc-induced accumulation of kerati-
nocytes in G2/M of the cell cycle (Figure 5D). Misu RNAi
did not trigger keratinocyte apoptosis or terminal differ-
entiation. On the contrary, a6b4 integrin expressionincreased and transglutaminase-1 expression de-
creased (Figures S5A–S5D).
Myc activation in the epidermis not only stimulates
proliferation but also promotes terminal differentiation
[6, 7]. To test whether this was also dependent on
Misu, we reconstituted human epidermis by growing
keratinocytes at the air-liquid interface on dead, de-epi-
dermized dermis (DED) [6] (Figures 5E–5P). Epidermis
formed by keratinocytes transduced with an empty ret-
roviral vector (k-eV) was well differentiated (Figures 5E
and 5I), with low numbers of proliferating cells in the
basal layer (Figure 5M). Epidermis reconstituted with
Misu-deficient keratinocytes (k-MisuRNAi) underwent
normal proliferation (Figure 5N) and terminal differentia-
tion, although the number of differentiated layers was
slightly reduced (Figures 5F and 5J).
As reported previously, keratinocytes infected with
MycER formed a multilayered epidermis with disorga-
nized suprabasal layers, more differentiated layers
(Figure 5G), and increased proliferation (Figure 5O) [6].
In the presence of Misu RNAi, these effects were abol-
ished (Figures 5H, 5L, and 5P). We conclude that Misu
RNAi prevents not only Myc-induced proliferation but
also Myc-induced terminal differentiation.
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zation of Misu and Effects of Misu RNAi on
Nucleolar Size
(A–H) RNA-dependent colocalization of Misu
with nucleolin in nucleoli. Immunofluores-
cence staining of Misu (A–D) and nucleolin
(E–H). SZ95 cells were treated with PBS (A,
E, and I), RNase (B, C, F, and G), or DNase
(D and H).
(I–L) Localization of Misu in nucleoli (arrows)
after treatment with PBS (I), 50 ng/ml actino-
mycin D (ActD, [J]), 10 mg/ml a-amanitin (K),
or 100 mg/ml a-amanitin (L).
(M) Western blots of Misu in (upper panel)
keratinocytes infected with empty vector
(pRS) or Misu RNAi constructs (RNAi1,3,4).
Lower panel shows keratinocytes coinfected
with empty vector (pBabe), RNAi4, or MycER
and treated with 4OHT.
(N–Q) Immunofluorescence staining of Misu
(green) and E-cadherin (red) in keratinocytes
infected with empty vector (k-pRS) or Misu
RNAi constructs.
(R–U) Activation of Myc increases keratino-
cyte nucleolar size in the absence (S and T)
but not the presence (U) of Misu RNAi. Cells
were transduced with the constructs shown.
Green fluorescence shows Misu. Blue fluo-
rescence shows DAPI. Scale bars represent
10 mm.Misu Is Expressed at Low Levels in Normal Tissues
and Is Upregulated in Tumors
Misu protein expression was very weak in human and
mouse skin, except in sebaceous glands and at the
bulb (base) of growing (anagen) hair follicles (Figures
6A, 6B, 6E, and 6F, data not shown). In K14MycER
mice treated with 4OHT for 4 days, Misu expression
was strongly increased, with immunoreactivity not only
in the sebaceous glands and hair-follicle bulb, but also
in the basal layer of the interfollicular epidermis and
along the hair-follicle outer root sheath (Figures 6C,
6D, 6G, and 6H), all the sites of transgene expression.
In all Misu-expressing cells, the protein had a nuclear
localization.
Misu expression was increased in benign (papillomas)
and malignant (squamous cell carcinomas) mouse skin
tumors (Figures 6I–6L; Table S1). In papillomas, cells ex-
pressing Misu were confined to the proliferative layers
(Figures 6I and 6J, arrow). In squamous cell carcinomas,the Misu-positive cells extended throughout the tumor
mass (Figures 6K and 6L). Two out of five human oral
squamous cell carcinomas were strongly positive for
Misu (Table S1 and data not shown).
Misu expression was very low in normal human tis-
sues (Table S1; Figures 6M and 6N and data not shown),
the only exception being the pancreas (Figure 6O). In the
colon, Misu was only expressed in a small number of ep-
ithelial cells (Figure 6S, arrowheads). However, in a pa-
tient with Crohn’s disease, there were areas of increased
expression (Figure 4U, arrowheads). It is interesting that
Myc is also upregulated in such tissue, and that Crohn’s
disease predisposes to gastric carcinoma [33].
Misu was upregulated in 7/7 human breast carcino-
mas, including primaries (Figures 6P and 6Q) and
lymph-node metastases (Figure 6R), and in 3/4 colon
carcinomas (Table S1). The only tumors that did not
show increased Misu expression were four rectal carci-
nomas (Table S1).
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(A–C) Introduction of Misu RNAi into keratinocytes transduced with MycER (k-MycER) or empty retroviral vector (k-pRS, k-pBabe) led to inhibi-
tion of proliferation. (A) and (B) show rhodamine-blue-stained culture dishes. (C) shows growth curves, and error bars represent standard de-
viations.
(D) Effect of Misu RNAi4 on Myc-induced changes in cell-cycle distribution.
(E–H) Histology and (I–P) immunofluorescence staining of keratinocytes cultured on DED. Keratinocytes were infected with empty vector (k-eV;
[E, I, and M]), Misu RNAi (F, J, and N), MycER (G, K, and O), or both Misu RNAi and MycER (H, L, and P) and grown in the presence of 4OHT.
Reconstituted epidermis was stained with antibody to transglutaminase 1 (TG1, [I–L]) or Ki67 (M–P) with DAPI counterstain (blue). Ki67-positive
cells are indicated with arrows. Scale bars represent 100 mm.
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sue and Tumors of Human and Mouse
(A–L) Histology (A–D) and Misu immunofluo-
rescence staining (E–H) (MFRY5) of wild-
type (A, B, E, and F) and K14MycER (C, D,
G, and H) mouse back skin after 4OHT treat-
ment. Arrows in (G) and (H) mark cells with
high Misu expression. Expression of Misu
was upregulated in mouse skin papilloma (I
and J) and squamous cell carcinoma (K and
L). Arrow in (J) shows Misu-positive cells.
(M–U) Immunohistochemistry for Misu in nor-
mal human lymph node (M), liver (N), pan-
creas (O), primary human breast carcinoma
(BC) (Q), lymph-node metastasis of breast
carcinoma (R), normal colonic epithelium
(S), colon carcinoma (T), and Crohn’s disease
(U). (P) As a control, staining of human breast
was performed with secondary antibody
alone.
Scale bars represent 50 mm (A–H) and 100 mm
(I–U).Knockdown of Misu Reduces Growth of Human
Squamous-Cell-Carcinoma Xenografts in Nude Mice
To investigate whether Misu RNAi could inhibit tumor
growth, we transduced a human squamous-cell-carci-
noma cell line, SCC15, with the RNAi constructs 1, 3,
and 4 and, as a control, with the empty vector pRS (Fig-
ure 7A). As in primary keratinocytes, RNAi4 reduced
Misu expression in SCC15 cells by 90%, whereas
RNAi1 and 3 were less effective (data not shown).
SCC15 cell proliferation in culture was not inhibited by
Misu knockdown (Figure 7A). However, when SCC15
cells infected with pRS or RNAi3 and 4 were subcutane-
ously injected into nude mice, tumor size was substan-
tially reduced by RNAi4 and, to a lesser extent, by
RNAi3 (Figure 7B).
SCC15 transduced with the empty vector pRS formed
squamous cell carcinomas with high Misu expression
and a large fraction of proliferative, Ki67-positive cells(Figures 7C, 7F, and 7I). SCC15 transduced with RNAi3
or 4 instead formed cysts containing cornified material
(Figures 7D and 7E). The number of Ki67- and Misu-pos-
itive cells was reduced by expression of RNAi3 or 4, the
effects being most dramatic with RNAi4 (Figures 7G, 7H,
7J, and 7K). We conclude that Misu repression inhibited
tumor growth in a dose-dependent manner.
Discussion
Misu is the first SUN-domain-containing protein to be
characterized in vertebrates. Although tRNAs are the
class of RNA with the highest number of nucleoside
modifications, only a few mammalian tRNA methylases
have been characterized [24, 34–37]. The different mod-
ifications are thought to affect maintenance of tRNA
structural integrity, translational efficiency, and/or fidel-
ity [38, 39].
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Growth
(A) Introduction of Misu RNAi constructs into
SCC15 cells did not affect proliferation
in vitro.
(B) Tumor growth was reduced when SCC15
cells infected with Misu RNAi3 and 4 were
xenografted into nude mice. pRS is control
vector. Error bars represent standard devia-
tions.
(C–E) Histology of tumors derived from
SCC15 infected with pRS (C), RNAi3 (D), or
RNAi4 (E).
(F–K) Immunohistochemistry of tumor sec-
tions stained with antibodies to Ki67 (F–H)
and Misu (I–K). Boxed regions in (I)–(K) are
shown at higher magnification in I–III. Dashed
line marks interface between tumor and
stroma in (J) and (K). Scale bar represents
100 mm.The localization of Misu in nucleoli is consistent with
recent evidence demonstrating that in yeast the majority
of tRNA processing takes place there [28, 29]. Most nu-
cleolar proteins are involved in ribosome biogenesis,
including synthesis and processing of rRNA [40]. Thus,
the nucleolus appears to be the site of most if not all
RNA editing, raising the possibility that the relative loca-
tions of tRNA, rRNA, and mRNA may be spatially coordi-
nated [41].
Nucleolar structure is dependent on RNA pol I and III
transcripts, rather than the activity of the RNA polymer-
ases themselves (Figures 4I–4L) [42]. Knockdown of
Misu prevented Myc-induced increase in nucleolar
size (Figures 4R–4U) [15]. Other factors that have the
same effect are nutrient restriction and inhibition of
TOR kinase, which results in a chromatin-mediated re-
arrangement of nucleolar architecture and RNA pol I lo-
calization [43]. Whether Misu has a similar effect on
RNA pol III remains to be elucidated, but we have pro-
vided evidence that Myc regulates nucleolar morphol-
ogy by directly activating a protein involved in RNA
processing.One difficulty in defining the role of the nucleolus in
cellular metabolism is that most of its structural and
functional proteins are continuously exchanged with
the nucleoplasm [44]. This was true for Misu, which
was found in the nucleolus in G1, throughout the nucle-
oplasm in S, dispersed in the cytoplasm in G2, and dec-
orating the spindle at M phase of the cell cycle. Misu
levels increased in S phase, and downregulation of
Misu in human primary keratinocytes prevented Myc-in-
duced accumulation of keratinocytes in G2/M [6]. These
observations suggest a possible role for Misu in regulat-
ing the cell cycle.
In conventional culture conditions, knockdown of
Misu decreased proliferation of human keratinocytes
and abolished Myc-induced hyperproliferation. How-
ever, when keratinocytes were growing at a low rate in
reconstituted epidermis, Misu RNAi did not affect prolif-
eration. This would argue that low levels of Misu are suf-
ficient for normal epidermal homeostasis, but Misu up-
regulation is required when keratinocyte proliferation is
stimulated, for example when cells enter the transit-am-
plifying compartment.
Current Biology
980Misu, like Myc, is overexpressed in human and animal
tumors [45]. Our xenograft data suggest that Misu medi-
ates the effects of Myc on tumor growth; Misu may also
contribute to the nucleolar changes associated with
malignant transformation [46].
Conclusion
Misu is a new Myc target gene that methylates RNA pol
III transcripts and is required for Myc-induced growth
and proliferation. We believe that Misu is not only the
key to understanding Myc functions in normal cells,
but is also an attractive target for anticancer therapies.
Supplemental Data
Supplemental Data include Supplemental Experimental Proce-
dures, five figures, and one table and are available with this article
online at: http://www.current-biology.com/cgi/content/full/16/10/
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